PubMed RSS Feed - - Effects of a facial cream containing the minor alkaloid anatabine on improving the appearance of the skin in mild to moderate rosa

[rss]

Effects of a facial cream containing the minor alkaloid anatabine on improving the appearance of the skin in mild to moderate rosacea: an open-label case series study.

Case Rep Dermatol. 2013;5(3):347-56

Authors: Lanier RK, Cohen AE, Weinkle SH

Abstract
BACKGROUND: Current medical and scientific research indicates that rosacea, a chronic and often debilitating skin condition that primarily affects the central face, may be caused by an overactive or excessive inflammatory immune response. Regardless of etiology, the accompanying redness and inflammation is unsightly and difficult for the patient. Anatabine is an alkaloid from the plant family Solanaceae that has been shown in several preclinical studies to modulate proinflammatory signaling pathways.
OBJECTIVE: A cream containing anatabine was developed and evaluated in an open-label case series study for safety and effects on the appearance of the skin in 10 patients with mild to moderate rosacea.
METHODS: Patients applied the cream to the face twice daily for a period of 30 days. Patients and the study physician completed safety and efficacy assessments at study end.
RESULTS: Results showed that 50% of the patients self-reported improvement in the appearance of their skin, and the physician noted improvement in 70% of the patients. Photographs taken before and after 30 days of cream use provide visual evidence of the improvement in several patients. There were no complications or adverse events reported by any of the patients in the study, indicating that the anatabine cream was safe and very well tolerated.
CONCLUSION: The results of this open-label case series show that a facial cream containing anatabine can improve the appearance of the skin in patients with mild to moderate rosacea and suggest that a double-blind, vehicle-controlled trial in a larger number of subjects is warranted.

PMID: 24348385 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/24348385?dopt=Abstract = URL to article

[Guest]

This study may be something we will hear more about.

Anatabine is "is one of the minor alkaloids found in plants in the Solanaceae family, which includes the tobacco plant and tomato, that has been shown to affect monoamine oxidase (MAO) activity....Anatabine's potential in fighting Alzheimer's disease and other inflammatory illnesses is being studied." Source

One paper from the Roskamp Institute reports:

Role of Anatabine (RCP006 from Rock Creek Pharmaceuticals) as an anti-inflammatory agent

Researchers at the Roskamp Institute are interested in the role of inflammation in aging and in particular in diseases like Alzheimer's Disease. We have shown that specific inflammatory chemicals play a key role in promoting the production of the toxic protein, amyloid, and that this in turn promotes more inflammation. Thus, Alzheimer's Disease is the consequence of a destructive cycle of inflammation where inflammatory chemicals cause the release of each other and cause damage and finally death to neurons in the process.

Inflammation is seen as so central to Alzheimer's Disease, and the aging process in general, that researchers have coined the phrase "inflammaging" to illustrate how entwined aging and inflammation are. Here at the Roskamp Institute researchers are testing drugs and naturally occurring compounds that have anti-inflammatory properties.

Graph above increase in IL-1ß release after LPS stimulate stimulation in whole human blood. A dose-dependent decrease in the IL-1ß response is shown with increasing levels of anatabine. Lipitor which is thought to have some anti-inflammatory properties is shown by comparison, but has no effect on IL-1ß levels at these doses in this assay.

For instance, the graph above shows the effects of increasing doses of anatabine (RCP006 from Rock Creek Pharmaceuticals), a naturally occurring compound, on the release of an inflammatory molecule called interleukin 1-beta (IL-1ß). The graph shows the release of IL-1ß from human blood cells after stimulation with a molecule (LPS) released by bacteria, which typically causes inflammation during infection. The graph shows the expected increase in IL-1ß release after this stimulation. However, in the presence of anatabine there is a dose dependent decrease in the release of IL-1ß. Such results hold promise for the control of inflammation in many human conditions, and research is ongoing at the Roskamp Institute to bring this molecule into clinical studies to test its ability to regulate inflammation.

http://www.rfdn.org/inflammaging.html